Table 4.
Breast cancer management.
| Total Population | <70 years-old | >70 years-old | p value | N | |
|---|---|---|---|---|---|
| Primary Surgery | 325 (99.7%) | 262 (100%) | 62 (98.4%) | 0.193 | 326 |
| Type of breast surgery | 0.079 | ||||
| Brest conservative | 222 (68.9%) | 185 (71.2%) | 37 (59.7%) | ||
| Mastectomy | 100 (31.1%) | 75 (28.8%) | 25 (40.3%) | ||
| Type of reconstruction | 0.014 | 325 | |||
| No reconstruction | 164 (50.5%) | 121 (46.0%) | 43 (69.4%) | ||
| Reconstruction | 161 (49.5%) | 142 (54%) | 19 (30.6%) | ||
| Post-op. Complications | 40(12.4%) | 33 (12.6%) | 7 (11.3%) | 0.939 | |
| Adjuvant CHT | 66 (20.4%) | 58 (22.2%) | 8 (12.7%) | 0.131 | 324 |
| Refused | 21 (100%) | 14 (100%) | 7 (100%) | . | 21 |
| Anthracyclines + alkylating agent | 5 (7.14%) | 4 (6.67%) | 1 (10%) | 0.105 | 70 |
| Taxanes + alkylating agent | 52 (74.3%) | 46 (76.7%) | 6 (60%) | ||
| 4 cycles | 58 (84.1%) | 51 (85%) | 7 (77.8%) | 0.095 | |
| 6 cycles | 7 (10.1%) | 7 (11.7%) | 0 (0.00%) | ||
| CHT assoc. complications | 11 (16.4%) | 10 (16.9%) | 1 (12.5%) | 1.000 | 67 |
| RT | 0.009 | 325 | |||
| Refusal | 20 (100%) | 15 (100%) | 5 (100%) | . | |
| RT Adjuvant | 253 (77.8%) | 213 (81.3%) | 40 (63.5%) | 0.004 | 325 |
| Total Dose (Gy) | 53.2 [25.0;66.4] | 53.2 [29.0;66.4] | 50.5 [25.0;66.4] | 0.041 | |
| Completed RT | 251 (77.2%) | 210 (80.2%) | 41 (65%) | 0.017 | 325 |
| Endocrine Therapy | 311 (95.4%) | 249 (94.7%) | 62 (98.4%) | 0.319 | 326 |
| Refused | 15 (100%) | 14 (100%) | 1 (100%) | 15 | |
| Adjuvant | 310 (95.1%) | 248 (94.3%) | 62 (98.4%) | 0.326 | 310 |
| Tamoxifen | 73 (23.9%) | 71 (28.9%) | 2 (3.33%) | <0.001 | |
| AI | 192 (62.7%) | 135 (54.9%) | 57 (95%) | ||
| Tamoxifen + GnRH | 3 (0.98%) | 3 (1.22%) | 0 (0.00%) | 319 | |
| AI plus GnRH | 20 (6.54%) | 20 (8.13%) | 0 (0.00%) | ||
| Sequential Tamoxifen-AI | 18 (5.88%) | 17 (6.91%) | 1 (1.67%) | ||
| Osteo-oncologic therapy | 145 (46.5%) | 108 (42.9%) | 37 (61.7%) | 0.013 | 312 |
| Denosumab | 31 (22.3%) | 20 (19.4%) | 11 (30.6%) | 0.440 | 139 |
| Bisphosphonates | 107 (77%) | 82 (79.6%) | 25 (69.4%) |